key: cord-0317852-eegidklc
authors: Arumahandi de Silva, A. N.; Frommert, L. M.; Albach, F. N.; Klotsche, J.; Scholz, V.; ten Hagen, A.; Jeworowski, L. M.; Schwarz, T.; Zernicke, J.; Corman, V. M.; Drosten, C.; Burmester, G. R.; Biesen, R.
title: Pausing methotrexate improves immunogenicity of COVID-19 vaccination in patients with rheumatic diseases
date: 2021-11-23
journal: nan
DOI: 10.1101/2021.11.17.21266441
sha: ee1d197e70567cdddf636f470dca282202d9ce17
doc_id: 317852
cord_uid: eegidklc

Objective: To study the effect of methotrexate (MTX) and its discontinuation on the humoral immune response after COVID-19 vaccination in patients with autoimmune rheumatic diseases (AIRD). Methods: Neutralising SARS-CoV-2 antibodies were measured after second vaccination in 64 rheumatic patients on methotrexate therapy, 31 of whom temporarily paused medication without a fixed regimen. The control group consisted of 21 AIRD patients without immunosuppressive medication. Results: MTX patients showed a significantly lower median antibody response compared to AIRD patients without immunosuppressive therapy (p< 0.001). Young age (<60 years) and MTX-hold after vaccination were found to be the main factors influencing antibody response after vaccination, while BMI or MTX dose demonstrated no effect. For patients taking MTX, age correlated negatively with immune response (r=-0.49; p<0.001) and all patients with antibody levels (14 %) below the cut-off were older than 60 years. Patients who held MTX during at least one vaccination showed significantly higher median neutralising antibody levels after second vaccination, compared to patients who continued MTX therapy during both vaccinations (68.82 %, 92.73 %, p=<0.001). This effect was particularly pronounced in patients older than 60 years (p=0.0016). The impact of the time period after vaccination was greater than of the time before vaccination with the critical cut-off being 10 days. Conclusion: MTX reduces the immunogenicity of SARS-CoV-2 vaccination in an age-dependent manner. Our data further suggest that holding MTX for at least 10 days after vaccination significantly improves the antibody response in patients over 60 years of age.

Until November 2021, SARS-CoV-2 had infected at least 250 million people worldwide and caused about 5 million deaths in a 23-month period 1 . At the same time, enormous knowledge about SARS-CoV-2 and the related disease COVID- 19 have been generated and the possibilities for prevention, diagnostics and treatments have improved remarkably.

Methotrexate (MTX) has been used for decades to treat a wide variety of immune-mediated diseases in oncology, rheumatology, dermatology, gastroenterology, and neurology. Following prednisolone, MTX is the most prescribed anti-inflammatory drug worldwide with 1 million MTX patients in the US alone 2 .

Various immunosuppressants reduce the immune response after COVID-19 vaccination and 40-44 % of hospitalised breakthrough infections happen to immunocompromised patients 3 4 .

Recently, MTX has also shown to reduce serological response after COVID-19 vaccination in three cohorts with a total of 60 patients 5 6 . The discontinuation of immunosuppressive medication can improve the vaccination response as recently shown for mycophenolate 7 .

A reduced vaccination response under MTX was first described in 2016 for influenza vaccination 8 . Follow-up data showed the increase in humoral immune response when pausing MTX two weeks before and after vaccination or only two weeks after vaccination 9 10 . The time after and not before vaccination was decisive 11 . Therefore, all current recommendations 12 for COVID -19 vaccinations under MTX therapy are based on experience with influenza vaccines, not considering mRNA-based technology used for COVID-19 vaccinations.

To understand the efficiency of MTX discontinuation during COVID-19 vaccination we analysed SARS-CoV-2-spike specific neutralising antibodies from patients receiving MTX and either continued therapy during both vaccinations (n=33) or a changed MTX schedule resulting in an intake gap longer than 7 days (n=31). is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

This report depicts results of the VACCIMMUN Study, which is a retrospective cohort study among patients with autoimmune rheumatic diseases (AIRD) at Charité Medical Clinic for Rheumatology and Clinical Immunology. Clinical characterisation and blood sampling took place between June and September 2021. In addition, stored blood samples collected in April and May 2021 were used. Participants had to meet the following inclusion criteria: age 18 years or older, AIRD diagnosis and vaccination with a COVID-19 vaccine authorised for use in Germany. For this analysis, AIRD patients under MTX therapy were considered, receiving either only MTX or MTX combined with low dose prednisolone (defined as ≤ 5 mg/d), TNFα-Inhibitors, hydroxychloroquine, leflunomide, IL-17 or IL-12/23 inhibitors, since these immunosuppressive comedications are not known to have a remarkable impact on the immune response during vaccination 13 . Additionally, AIRD patients who were vaccinated under no immunosuppressive therapy served as controls. Information regarding medical history, including COVID-19 vaccination status and immunosuppressive therapy were provided directly by patients or retrieved from medical records. Patients who reported to have changed their MTX-intake schedule resulting in an MTX-interval longer than 7 days during first or second vaccination were compared to patients who continued MTX therapy throughout both vaccinations. This study was ethically approved by the Regional Office for Health and Social Affairs Berlin, Germany (21/0098-IV E 13). All patients provided written informed consent.

Antibody response was measured predominantly about two weeks after the second dose of vaccination with maximum range from 11 to 112 days (Median 20, IQR 15, 47) . Neutralising antibody levels were assessed using a surrogate virus neutralisation test (cPass Neutralisation, Medac GmbH, Wedel, Germany) 14 . Following the manufacturer's protocol, patients who reached inhibition rates greater than or equal to 30 % were considered to have demonstrated a SARS-CoV-2 specific humoral response and are further defined as responders, while patients with inhibition rates <30 % are defined as non-responders. Additionally, IgG antibodies against nucleocapsid, receptor binding domain (RBD), full spike and the S1 domain of the spike protein were tested using SeraSpot® Anti-SARS-CoV-2 IgG microarray-based immunoassay (Seramun Diagnostica GmbH, Heidesee, Germany) and served here for further validation purposes.

Hence, all calculations were additionally performed using anti-RBD-IgG levels and can be found in the supplements. The threshold for reactivity for anti-SARS-CoV-2 IgG levels was set at >1.00

Signal/Cut-off (S/CO) in accordance with manufacturer´s protocol.

Descriptive statistics included median with interquartile range and absolute and relative frequencies. Fisher's exact test and Chi² test were applied for categorical data and the Mann-Whitney U test for continuously distributed variables to perform hypotheses tests for group differences, as appropriate. The likelihood of being a responder was modelled by a multivariable logistic regression model including the covariates age, body mass index (BMI), gender, MTX monotherapy and MTX-hold. These covariates were selected based on the theoretical assumption that they could affect vaccination success. The association between timing and duration of MTX-hold at the two vaccinations and neutralisation results were 

This study aimed to provide evidence for future recommendations due to questions asked regarding MTX intake by patients and physicians. However, patients and the public were not directly involved in process of designing. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint 

. CC-BY-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 23, 2021. ; https://doi.org/10.1101/2021.11.17.21266441 doi: medRxiv preprint

To identify factors influencing the antibody response under MTX we compared COVID-19vaccination responders (n=55, 85.9 %) and non-responders (n=9, 14.1 %) defined by neutralisation activity. Both groups were similar in BMI, vaccine type, MTX application form, additional prednisolone intake, time of blood draw and immunosuppressive comedication (table 1). Dosage of MTX was not significantly associated with vaccination success (Spearman rank test, r=-0.02, p value=0.867). However, a higher neutralization capacity was significantly associated with young age, MTX-hold and female gender in univariate analysis (table 1) and multivariable analysis (table 3) . If classification into responders and non-responders was based on anti-RBD-IgG results, 13 patients fall into the non-responder group. While the effect of age and MTX-hold were still significant using anti-RBD-IgG levels, this was not the case for gender (supplementary table 2 ). Thus, we only analysed the effect of age and MTX-hold in more detail.

Patients who had changed their MTX intake schedule for at least one vaccination showed a significantly higher antibody response than patients who continued their MTX intake (p=0.003, is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 23, 2021. ; https://doi.org/10.1101/2021.11.17.21266441 doi: medRxiv preprint

Due to the observational design of this study, patients were not instructed to hold MTX in a certain pattern, which resulted in a wide distribution of MTX intake regimens.

In the following we considered all 64 patients and analysed the MTX-interval at the time of vaccination, which was defined by the time between last MTX intake and vaccination (time before vaccination = TBV) and the time between vaccination and re-intake of MTX (time after vaccination = TAV, figure 4). One patient could not recall on which day MTX was taken and was therefore not considered for calculations of TBV and TAV. We found that the duration of the MTX-interval (TBV + TAV) significantly correlates with neutralising capacity (Spearman rank test, r = 0.47, p< 0.001). We further analysed which of these time periods is most likely to determine antibody response. By using linear regression analysis, we found TAV to be highly significant for adequate neutralisation rate and anti-RBD-IgG concentration in the elderly, but not for younger patients (table 4) . Here, ten days between vaccination and MTX re-intake (TAV) were determined as the critical cut-off based on the Youden index from receiver operating characteristic curve. TBV was only significant when regarding neutralisation capacity (table 4 ).

In addition, the standardized beta value was higher for TAV (betast 0.40) than for TBV (betast 0.07).

. CC-BY-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 23, 2021. ; https://doi.org/10.1101/2021.11.17.21266441 doi: medRxiv preprint

Our study emphasizes a severely reduced COVID-19 vaccination response in elderly MTX patients, demonstrates the benefit of MTX-hold and delivers first evidence for possible recommendations for further COVID-19 vaccinations.

Using neutralising capacity and the manufacturer's cut-off, we found a slightly higher rate of vaccination responders among patients taking MTX (85.9 %) than previously reported (47 -72 %) 5 6 . This might be due to the inclusion of patients who held MTX during vaccinations in our study. Using ROC analysis and an untreated control group, we found determined an adapted cut-off value and found adequate immune response in only 40.6 % of MTX patients. Hence, by regarding 64 MTX patients and a control group (n = 21) we confirmed the observations from previous studies that the antibody response is reduced under MTX therapy.

We determined young age, MTX-hold and female gender as the main factors influencing antibody response after vaccination. The negative influence of age on vaccination response was already known 15 16 , however, the consideration of age was not yet differentiated in previous studies investigating immune response under MTX therapy. Our data allows the assumption that continuous MTX intake and old age are potentiating negative influences on humoral immune response after COVID-19 vaccination.

Patients who held MTX for at least one vaccination had a significantly higher immune response than those who continued MTX, which has not yet been described for COVID-19 vaccination.

Nevertheless, our findings are in line with studies by Park et al. investigating the effect of MTXhold on the immune response to influenza vaccination 9 17 . More detailed analysis showed that time after vaccination is crucial, which was also described by Park et al. who recommended a MTX discontinuation of two weeks after influenza vaccination 10 11 . Also, current guidelines by the American College of Rheumatology as well as the German Society for Rheumatology recommend holding MTX one to two weeks after COVID-19 vaccination 12 13 . In our study, we found a minimum time of 10 days after vaccination to be critical for immune response in is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 23, 2021. ; https://doi.org/10.1101/2021.11.17.21266441 doi: medRxiv preprint positive effect of MTX-hold was only statistically significant for patients 60 years or older. An effect also in younger patients might be observed in a larger cohort.

We validated all our neutralisation test results with an additional test system measuring anti-RBD-IgG levels. The latter defined four more patients as non-responders compared to the neutralisation test. This small number of conflicting test results is to be expected when using different test systems, especially for systems that do or do not distinguish between Ig subtypes and did not have an impact when validating our calculations. However, the uneven distribution of gender, among patients who had conflicting test results, caused our analyses to suggest a significant influence of gender on the neutralisation result may be due a statistical artifact and the effect of gender should be interpreted with caution and the effect of gender should be revised in an external larger cohort.

Limitations of our study were small case numbers and the retrospective design, which is why our findings should be validated in a randomized controlled trial in the future. Also, T-cellresponse were not part of our study design, however, according to current studies, it can be assumed that measuring antibody levels is an adequate mean to determine vaccine immunogenicity 18 . In addition, we used multivariable statistical models analyses to additionally adjust for the potential confounders MTX monotherapy and MTX dose. A strength of our study was that we validated all our neutralisation test results with an additional test system measuring anti-RBD-IgG. We did not assess the safety of pausing MTX in our cohort, but current data do not indicate a significantly higher flare occurrence or disease activity in association with MTX discontinuation of two weeks 19 .

In conclusion, we present real-world data that is of clinical relevance regarding upcoming booster vaccination campaigns initiated by several countries. We determined age and MTXhold as the main factors influencing antibody response during SARS-CoV-2 vaccinations and both aspects should be regarded when discussing MTX regimens. Our data suggest that, if possible, patients older than 60 years of age should hold MTX for at least 10 days after receiving a COVID-19-vaccination. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint 

 This study identified old age (≥ 60 years) and MTX continuation as critical factors for an inadequate antibody response.

 We found a minimum of 10 days between vaccination and re-intake of MTX as the critical threshold to increase immunogenicity for patients ≥ 60 years of age.

 In regard of upcoming booster vaccination campaigns, our data suggest that especially older MTX patients should hold MTX for at least 10 days after receiving a COVID-19 vaccination, if possible. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 23, 2021. ; https://doi.org/10.1101/2021.11.17.21266441 doi: medRxiv preprint support in obtaining the ethics vote and for their organisational support. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 23, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 23, 2021. ; https://doi.org/10.1101/2021.11.17.21266441 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 23, 2021. ; https://doi.org/10.1101/2021.11.17.21266441 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 23, 2021. ; is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 23, 2021. ; Figure 1: Comparison is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 23, 2021. ; https://doi.org/10.1101/2021.11.17.21266441 doi: medRxiv preprint

patients who held MTX during vaccination (n=33) and patients who continued MTX-therapy (n=31). (B) Anti-RBD-IgG concentrations differentiated by age groups <60 years and ≥60 years. P values were calculated using the non-parametric Mann Whitney U test. Dotted line marks the cut-off value following manufacturer's protocol (>1 S/CO). Yellow squares represent patients who continued MTX-therapy, purple dots represent patients who held MTX for at least one vaccination.

Purple dots represent patients who held MTX during vaccination (n=31), yellow squares represent patients who continued MTX-therapy (n=33). Dotted lines mark the cut-off antibody concentration for adequate humoral immune response following manufacturer's protocol (>1 S/CO) and the cut-off age observed for this cohort at 60 years. P value and correlation coefficient were calculated using the Spearman Rank test.

. CC-BY-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 23, 2021. ; https://doi.org/10.1101/2021.11.17.21266441 doi: medRxiv preprint

Coronavirus Pandemic (COVID-19): Our World in Data

BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel

Effectiveness of SARS-CoV-2 mRNA Vaccines for Preventing Covid-19 Hospitalizations in the United States

The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study

Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease. clinical trial

Optimal time between the last methotrexate administration and seasonal influenza vaccination in rheumatoid arthritis: post hoc analysis of a randomised clinical trial

American College of rheumatology guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: version 4

Aktualisierte Handlungsempfehlungen der Deutschen Gesellschaft für Rheumatologie für die Betreuung von Patienten mit entzündlichrheumatischen Erkrankungen im Rahmen der SARS-CoV-2/COVID-19-Pandemie einschließlich Empfehlungen zur COVID-19-Impfung

A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction

Delayed antibody and T-cell response to BNT162b2 vaccination in the elderly

Age-dependent immune response to the Biontech/Pfizer BNT162b2 COVID-19 vaccination. medRxiv : the preprint server for health sciences

Effect of methotrexate discontinuation on efficacy of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

Effect of short-term methotrexate discontinuation on rheumatoid arthritis disease activity: post-hoc analysis of two randomized trials

* P values were calculated using Fisher`s exact test or Chi² test for categorical variables and Mann-Whitney U test for continuous variables

Axial spondyloarthritis (n=2), Polymyalgia rheumatica (n=3), Primary Sjogren's syndrome (n=1), Myositis (n=2)

Polymyalgia rheumatica (n=1), Primary Sjogren's syndrome (n=2)

AZD1222 + BNT162b2 (n=2). No-therapy-group: AZD1222 + BNT162b2 (n=1), AZD1222 + mRNA-1273 (n=1)

§ Defined by neutralising capacity against SARS-CoV-2 ≥ 30 %

We would like to thank Tanja Braun and Vera Höhne-Zimmer for their